Peptide PT-141 dosage is 1.75 mg injected under the skin at least 45 minutes before sex, no more than once daily and eight times monthly. See the guide.
The FDA-approved peptide PT-141 dosage is 1.75 mg injected subcutaneously, usually in the abdomen or thigh, at least 45 minutes before anticipated sexual activity. This dose comes from Vyleesi, the only bremelanotide product approved in the United States, and it is limited to once every 24 hours and no more than eight times per month. No other route or dose of PT-141 is FDA-approved for human use.
PT-141 Dosing Basics: The FDA-Approved Regimen
PT-141 (bremelanotide) is a melanocortin receptor agonist that affects the central nervous system. The approved product, Vyleesi, is a prefilled autoinjector that delivers 1.75 mg under the skin. The label instructs users to inject into the abdomen or thigh and to take the dose at least 45 minutes before sexual activity.
Do not take more than one dose in 24 hours. Do not use more than eight doses in a month. Exceeding these limits increases the chance of side effects without adding benefit. The medication is not meant for continuous daily use.
PT-141 Dosage for Men vs. Women
The FDA-approved indication for Vyleesi is hypoactive sexual desire disorder (HSDD) in premenopausal women. There is no approved pt 141 dosage for men in the United States. Men who use PT-141 do so off-label, and the safety and effectiveness in men have not been established by the FDA.
| Group | FDA-approved dose | Frequency limit | Status |
|---|---|---|---|
| Premenopausal women with HSDD | 1.75 mg subcutaneous | Max 1 dose/24 hours; max 8 doses/month | FDA-approved (Vyleesi) |
| Men | No approved dose | Not established | Off-label only |
| Postmenopausal women | No approved dose | Not established | Off-label only |
Some research studies have explored higher or repeated doses, but those protocols are not the same as approved clinical use. A healthcare professional can explain whether off-label use is appropriate for a specific patient.
Nasal Spray and Other Unapproved Routes
Before the injectable form was approved, bremelanotide was studied as a nasal spray. Those trials used different doses and produced inconsistent results, partly because absorption through the nasal lining varies from person to person. Today, no nasal spray version of PT-141 is FDA-approved for any use.
People who ask about pt 141 peptide spray dosage are usually looking for a needle-free option, but no spray form is FDA-approved. Without approved labeling, there is no standard, safe dose to follow. The same is true for any topical, sublingual, or oral PT-141 product sold online.
PT-141 Side Effects and Safety Warnings
The most commonly reported pt 141 peptide side effects are nausea, flushing, headache, and injection site reactions. Nausea is the most frequent reason people stop using the medication. PT-141 can also cause a transient increase in blood pressure, so it is not recommended for people with uncontrolled hypertension or known cardiovascular disease.
Other precautions include:
- Limit alcohol use during treatment, because alcohol can worsen nausea and blood pressure changes.
- Do not use PT-141 if you are pregnant or breastfeeding.
- Tell your healthcare provider about all medications you take, especially blood pressure drugs.
- Seek immediate medical attention for severe headache, chest pain, or signs of a hypertensive crisis.
Sourcing, Legality, and What Reviews Say
Websites that list pt 141 peptide for sale often operate outside FDA oversight. These products may be mislabeled, contaminated, or not sterile. A search for pt-141 peptide buy typically surfaces research chemical vendors rather than licensed pharmacies. Only a licensed pharmacy should dispense an FDA-approved product with a prescription.
Online pt-141 peptide reviews and nasal spray reviews are highly variable. Some users report increased desire, while others report nausea or no effect. These anecdotal reports are not a substitute for clinical evidence, and the FDA-approved injectable has the most reliable safety data.
How to Use PT-141 Safely
If you are prescribed Vyleesi, follow the label exactly. Do not adjust the dose on your own, and do not use it more often than recommended. Tell your healthcare provider about all medical conditions and medications before you start.
- Use only under medical supervision.
- Do not share your prescription with anyone else.
- Store the autoinjector as directed on the packaging.
- Report any new or worsening side effects to your provider.
PT-141 is not a cure for sexual dysfunction, and it does not work for everyone. A healthcare professional can help you weigh the benefits and risks based on your health history.
Key Takeaways
- The only FDA-approved PT-141 dosage is 1.75 mg injected subcutaneously, no more than once per 24 hours and no more than eight times per month.
- PT-141 is not FDA-approved for men or for nasal spray use in the United States.
- Common side effects include nausea, flushing, headache, and temporary blood pressure increases.
- Buying PT-141 from research chemical websites carries unknown safety and legal risks.
Frequently Asked Questions
What is the typical PT-141 dosage for men?
There is no FDA-approved PT-141 dosage for men. Vyleesi, the only approved bremelanotide product, is indicated only for premenopausal women with hypoactive sexual desire disorder. Men who use PT-141 do so off-label, and research has not established safe or effective dosing for them.
How often can you take PT-141?
The FDA-approved regimen is a single 1.75 mg subcutaneous injection no more than once in 24 hours and no more than eight times per month. Using it more often increases the risk of nausea, flushing, and blood pressure changes without improving results.
Is PT-141 nasal spray FDA-approved?
No. The only FDA-approved bremelanotide product is Vyleesi, a subcutaneous injection. Nasal spray forms of PT-141 are sold online as research chemicals and are not approved for human use in the United States.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.